Balaxi Pharma as a stock is very attractively valued. However 40% or so of their revenue comes from Angola which is facing hyperinflation. So that’s the current risk which is putting downward pressure on its revenues. Else the business model is strong
| Subscribe To Our Free Newsletter |
